INDICATION

LUMAKRAS^® is indicated for the treatment of adult patients with KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC), as determined by an FDA‑approved test, who have received at least one prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Request a rep

Office tool kit Dispensing resources Other helpful resources

Office tool kit

New_web_icons_Fact Sheet 2

Access guide

Contains dosing guidelines, coverage and co-pay details, and resources

Prior authorization guide

Information on navigating the payer approval process

New_web_icons_Fact Sheet 2

Sample Letter of Medical Necessity

See how to craft a Letter of Medical Necessity for your patients

New_web_icons_Flyer 2

Sample letter of appeal

Example of how to appeal the denial of coverage for LUMAKRAS^®

Dispensing resources

New_web_icons_Fact Sheet 2

Product Fact sheet

Includes product information, description, storage requirements, and contact information for coverage questions

New_web_icons_Flyer 2

LUMAKRAS^® specialty pharmacy and distributors list

Contact information for the pharmacies in the LUMAKRAS^® network

Other helpful resources

New_web_icons_Fact Sheet 2

LUMAKRAS® dose modification fact sheet

New_web_icons_Flyer 2

Patient brochure

fact_sheet 1

Dosing flyer for your patients

roadmap 1

Access roadmap for your patients

New_web_icons_Fact Sheet 2

Patient profiles

Visit our patient site for more LUMAKRAS^® resources

IMPORTANT SAFETY INFORMATION

Hepatotoxicity

LUMAKRAS^® can cause hepatotoxicity and increased ALT or AST which may lead to drug-induced liver injury and hepatitis.
In the pooled safety population of NSCLC patients who received single agent LUMAKRAS^® 960 mg hepatotoxicity occurred in 27% of patients, of which 16% were Grade ≥ 3. Among patients with hepatotoxicity who required dosage modifications, 64% required treatment with corticosteroids.
In this pooled safety population of NSCLC patients who received single agent LUMAKRAS^® 960 mg, 17% of patients who received LUMAKRAS^® had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); of which 9% were Grade ≥ 3. The median time to first onset of increased ALT/AST was 6.3 weeks (range: 0.4 to 42). Increased ALT/AST leading to dose interruption or reduction occurred in 9% of patients treated with LUMAKRAS^®. LUMAKRAS^® was permanently discontinued due to increased ALT/AST in 2.7% of patients. Drug-induced liver injury occurred in 1.6% (all grades) including 1.3% (Grade ≥ 3).
In this pooled safety population of NSCLC patients who received single agent LUMAKRAS^® 960 mg, a total of 40% patients with recent (≤ 3 months) immunotherapy prior to starting LUMAKRAS^® had an event of hepatotoxicity. An event of hepatotoxicity was observed in 18% of patients who started LUMAKRAS^® more than 3 months after last dose of immunotherapy and in 17% of those who never received immunotherapy. Regardless of time from prior immunotherapy, 94% of hepatotoxicity events improved or resolved with dosage modification of LUMAKRAS^®, with or without corticosteroid treatment.
Monitor liver function tests (ALT, AST, alkaline phosphatase, and total bilirubin) prior to the start of LUMAKRAS^®, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations. Withhold, reduce the dose or permanently discontinue LUMAKRAS^® based on severity of the adverse reaction. Consider administering systemic corticosteroids for the management of hepatotoxicity.

Interstitial Lung Disease (ILD)/Pneumonitis

LUMAKRAS^® can cause ILD/pneumonitis that can be fatal.
In the pooled safety population of NSCLC patients who received single agent LUMAKRAS^® 960 mg ILD/pneumonitis occurred in 2.2% of patients, of which 1.1% were Grade ≥ 3, and 1 case was fatal. The median time to first onset for ILD/pneumonitis was 8.6 weeks (range: 2.1 to 36.7 weeks). LUMAKRAS^® was permanently discontinued due to ILD/pneumonitis in 1.3% of LUMAKRAS^®-treated patients. Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold LUMAKRAS^® in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS^® if no other potential causes of ILD/pneumonitis are identified.

Most Common Adverse Reactions

The most common adverse reactions ≥ 20% were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough.

Drug Interactions

Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over‑the‑counter drugs, vitamins, dietary and herbal products.
Inform patients to avoid proton pump inhibitors and H2 receptor antagonists while taking LUMAKRAS^®.
If coadministration with an acid-reducing agent cannot be avoided, inform patients to take LUMAKRAS^® 4 hours before or 10 hours after a locally acting antacid.

INDICATION

LUMAKRAS^® is indicated for the treatment of adult patients with KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC), as determined by an FDA‑approved test, who have received at least one prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Please see full LUMAKRAS^® Prescribing Information.